Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varenicline for Methamphetamine Dependence (RAVEN)
NCT01011829Phase 2
Key facts
- Status
- Completed
- Start
- Nov 2009
- Primary completion
- May 2010
- Countries
- 1
- Sponsor
- University of California, Los Angeles
- Drugs
- varenicline
- Conditions
- methamphetamine use disorder (MUD)
01
Overview
Phase 2, randomised, double-blind trial of varenicline in methamphetamine use disorder (MUD), sponsored by University of California, Los Angeles. Primary endpoint: Change in Methamphetamine Positive Urine Drug Screens at 8 weeks. Started Nov 2009; status: completed.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Adults aged 18 or older meeting DSM-IV criteria for methamphetamine dependence seeking treatment, excluding those with other substance dependencies, major psychiatric disorders, or significant medical conditions.
04
Endpoints
Primary
Change in Methamphetamine Positive Urine Drug Screens
Secondary
Treatment Retention
Beyond the preview
Go deeper on NCT01011829.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01011829.